You are here:

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)

posted 14/03/2016

publication GW Pharmaceuticals

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)
- Study in the Treatment of Dravet Syndrome – a rare and severe form of epilepsy in children with no FDA-approved treatments -
- Primary endpoint achieved with high statistical significance (p=0.01) showing that Epidiolex treatment reduces convulsive seizures in children compared to placebo –

articles

get involved

If you are interested in what we do and would like to support our work, find out more ways to get involved.

Donate

get our book

Drugs: It’s just not worth it

Our 35-page book gives clear and easy to read facts and advice aimed at teenagers and young people.

£3.00